Showing results (51-60 of 76) with videos related to
Sort By:
Pageof 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021
Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung CancerAnna-Larissa N Niemeijer, Daniela E Oprea-Lager, Marc C Huisman, et al.Nature Reviews. Clinical Oncology|March 15, 2025
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trialsSophie M Ernst, Mihaela Aldea, Jan H von der Thüsen, et al.The Lancet. Oncology|August 1, 2024
Dose selection of novel anticancer drugs: exposing the gap between selected and required dosesCatharina J P Op 't Hoog, Niven Mehra, Marc Maliepaard, et al.Cancers|December 9, 2023
89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy OrgansIris H C Miedema, Jessica E Wijngaarden, Johanna E E Pouw, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 16, 2020
Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung CancerMarc C Huisman, Anna-Larissa N Niemeijer, Albert D Windhorst, et al.Neuro-Oncology|August 7, 2024
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases studyJ W Tijmen van der Wel, Mirjam C Boelens, Merel Jebbink, et al.Journal for Immunotherapy of Cancer|June 17, 2024
Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by 18F-BMS986-192 PET: pooled analysis of data from four solid tumor typesIris H C Miedema, Johanna E E Pouw, Anne Kwakman, et al.Oncotarget|May 8, 2018
Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysisRobin W Jansen, Paul van Amstel, Roland M Martens, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 13, 2021
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung CancerJasper Smit, Frank J Borm, Anna-Larissa N Niemeijer, et al.CPT: Pharmacometrics & Systems Pharmacology|February 26, 2025
Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET-Guided VerificationSuzanne van der Gaag, Tamara Jordens, Maqsood Yaqub, et al.Pageof 8